A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, ...

Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the risk of heart attacks and strokes, according to a study in The Lancet.

aDepartment of Paediatrics and Department of Pathology, Immunology and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL, USA ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

Lancets play an integral part in glucose monitoring for diabetes management as single-use designs help ensure safety and hygiene thereby decreasing risks of infections or cross-contamination ...